LT4551B - 4-[5-metil-3-fenilizoksazol-4-il]benzensulfonamido kristalinė forma - Google Patents

4-[5-metil-3-fenilizoksazol-4-il]benzensulfonamido kristalinė forma Download PDF

Info

Publication number
LT4551B
LT4551B LT99-024A LT99024A LT4551B LT 4551 B LT4551 B LT 4551B LT 99024 A LT99024 A LT 99024A LT 4551 B LT4551 B LT 4551B
Authority
LT
Lithuania
Prior art keywords
methyl
benzenesulfonamide
treatment
phenylisoxazol
methanol
Prior art date
Application number
LT99-024A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT99024A (en
Inventor
John J. Talley
John R. Medich
Kathleen T. Mclaughlin
Henry T. Gaud
Edward E. Yonan
Original Assignee
G.D. Searle & Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G.D. Searle & Co. filed Critical G.D. Searle & Co.
Publication of LT99024A publication Critical patent/LT99024A/xx
Publication of LT4551B publication Critical patent/LT4551B/lt

Links

Classifications

    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/40—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs
    • H01L23/4006—Mountings or securing means for detachable cooling or heating arrangements ; fixed by friction, plugs or springs with bolts or screws
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L23/00—Details of semiconductor or other solid state devices
    • H01L23/34—Arrangements for cooling, heating, ventilating or temperature compensation ; Temperature sensing arrangements
    • H01L23/42—Fillings or auxiliary members in containers or encapsulations selected or arranged to facilitate heating or cooling
    • H01L23/427—Cooling by change of state, e.g. use of heat pipes
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/0001—Technical content checked by a classifier
    • H01L2924/0002—Not covered by any one of groups H01L24/00, H01L24/00 and H01L2224/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Computer Hardware Design (AREA)
  • Power Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)
  • Liquid Crystal Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
LT99-024A 1996-08-14 1999-03-10 4-[5-metil-3-fenilizoksazol-4-il]benzensulfonamido kristalinė forma LT4551B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2437896P 1996-08-14 1996-08-14

Publications (2)

Publication Number Publication Date
LT99024A LT99024A (en) 1999-07-26
LT4551B true LT4551B (lt) 1999-10-25

Family

ID=21820280

Family Applications (1)

Application Number Title Priority Date Filing Date
LT99-024A LT4551B (lt) 1996-08-14 1999-03-10 4-[5-metil-3-fenilizoksazol-4-il]benzensulfonamido kristalinė forma

Country Status (39)

Country Link
US (2) US6441014B2 (fr)
EP (2) EP0920422B1 (fr)
JP (2) JP3631763B2 (fr)
KR (1) KR100383148B1 (fr)
CN (1) CN1205193C (fr)
AP (1) AP1055A (fr)
AR (1) AR009244A1 (fr)
AT (1) ATE228117T1 (fr)
AU (1) AU722072B2 (fr)
BG (1) BG64259B1 (fr)
BR (1) BR9711151A (fr)
CA (1) CA2264104A1 (fr)
CZ (1) CZ297679B6 (fr)
DE (1) DE69717281T2 (fr)
DK (1) DK0920422T3 (fr)
EA (2) EA003754B1 (fr)
EE (1) EE04237B1 (fr)
ES (1) ES2188971T3 (fr)
GE (1) GEP20022636B (fr)
HK (1) HK1023125A1 (fr)
HU (1) HUP0400923A3 (fr)
IL (2) IL161224A0 (fr)
IS (1) IS1989B (fr)
LT (1) LT4551B (fr)
LV (1) LV12274B (fr)
NO (1) NO312461B1 (fr)
NZ (1) NZ334132A (fr)
OA (1) OA11298A (fr)
PL (1) PL191313B1 (fr)
PT (1) PT920422E (fr)
RO (1) RO120771B1 (fr)
RS (1) RS49671B (fr)
SI (1) SI9720059B (fr)
SK (1) SK283558B6 (fr)
TR (1) TR199900298T2 (fr)
TW (1) TW527350B (fr)
UA (1) UA52684C2 (fr)
WO (1) WO1998006708A1 (fr)
ZA (1) ZA977314B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE228117T1 (de) * 1996-08-14 2002-12-15 Searle & Co Kristalline form von 4-(5-methyl-3-phenylisoxazol-4-yl)benzolsulfona id
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
GB9810920D0 (en) * 1998-05-21 1998-07-22 Merck Sharp & Dohme Therapeutic use
EP1102755B1 (fr) * 1998-08-07 2006-01-04 Chiron Corporation Isoxazoles substitues comme modulateurs de recepteur d'oestrogenes
AU1398899A (en) * 1998-11-12 2000-06-05 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
NZ513924A (en) * 1999-03-01 2001-09-28 Ortho Mcneil Pharm Inc Composition comprising a tramadol material and a selective cox-2 inhibitor drug
HUP0203198A3 (en) * 1999-08-20 2005-07-28 Ortho Mcneil Pharm Inc Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
EP1212051A4 (fr) * 1999-08-27 2004-03-31 Merck & Co Inc Methode de traitement ou de prevention de la prostatite chronique ou du syndrome de la douleur pelvienne chronique
DE10032132A1 (de) * 2000-07-01 2002-01-17 Lohmann Therapie Syst Lts Dermales Therapeutisches System enthaltend nichtsteroidale Antiphlogistika mit selektiver COX-2-Hemmung
CN100439360C (zh) 2001-08-15 2008-12-03 法玛西雅厄普约翰美国公司 包括n-[2-(二乙氨基)乙基]-5-[(5-氟-2-氧代-3h-吲哚-3-亚基)甲基]-2,4-二甲基-1h-吡咯-3-甲酰胺的苹果酸盐的晶体、其制备方法和其组合物
US20070072921A1 (en) * 2002-07-26 2007-03-29 Talley John J Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
US7538126B2 (en) 2003-04-04 2009-05-26 Hetero Drugs Limited Crystalline forms of valdecoxib
PT1534305E (pt) 2003-05-07 2007-02-28 Osteologix As Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis
US20050182113A1 (en) * 2003-12-30 2005-08-18 Venkataraman Sundaram Method for preparing diaryl-substituted isoxazole compounds
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib
WO2005120499A1 (fr) * 2004-06-10 2005-12-22 Chandiran Thakashinamoorthy Forme de valdecoxib adaptee pour des compositions pharmaceutiques
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
EP1612203B1 (fr) * 2004-06-28 2007-08-01 Grünenthal GmbH Formes cristallines de chlorhydrate de (-)-(1R,2R)-3-(3-diméthylamino-1-ethyl-2-méthylpropyl)-phénol
KR100591786B1 (ko) 2004-10-19 2006-06-26 휴먼팜 주식회사 프란루카스트를 함유하는 약학적 조성물 및 이의 제조 방법
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
EA200870556A1 (ru) 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
NZ590682A (en) 2008-06-23 2012-09-28 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103172583A (zh) * 2013-03-07 2013-06-26 深圳市资福药业有限公司 一种制备帕瑞昔布的方法
US9375417B2 (en) 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
US10028904B2 (en) 2014-12-04 2018-07-24 Wisconsin Alumni Research Foundation Transdermal cannabinoid formulations
CN114441666B (zh) * 2020-11-05 2024-02-27 成都百裕制药股份有限公司 一种4-(5-甲基-3-苯基-4-异恶唑)苯磺酰氯中杂质的检测方法
CA3209491A1 (fr) 2021-03-15 2022-09-22 Saul Yedgar Dipalmitoyl-phosphatidyl-ethanol-amine conjuguee a l'acide hyaluronique en combinaison avec des medicaments anti-inflammatoires non steroidiens (ains) pour traiter ou soulager des maladies inflammatoire

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025405A1 (fr) 1995-02-13 1996-08-22 G.D. Searle & Co. Isoxazoles substitues utilisables dans le traitement d'inflammations
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
ATE228117T1 (de) * 1996-08-14 2002-12-15 Searle & Co Kristalline form von 4-(5-methyl-3-phenylisoxazol-4-yl)benzolsulfona id
US7538126B2 (en) * 2003-04-04 2009-05-26 Hetero Drugs Limited Crystalline forms of valdecoxib
US20050272787A1 (en) * 2004-05-19 2005-12-08 Eswaraiah Sajja Process for preparing crystalline form A of valdecoxib

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025405A1 (fr) 1995-02-13 1996-08-22 G.D. Searle & Co. Isoxazoles substitues utilisables dans le traitement d'inflammations
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation

Also Published As

Publication number Publication date
EA001472B1 (ru) 2001-04-23
EE04237B1 (et) 2004-02-16
AU722072B2 (en) 2000-07-20
NZ334132A (en) 2000-06-23
SI9720059A (sl) 1999-12-31
AR009244A1 (es) 2000-04-12
EP0920422B1 (fr) 2002-11-20
WO1998006708A1 (fr) 1998-02-19
US20030004200A1 (en) 2003-01-02
HUP0400923A2 (hu) 2004-08-30
EE9900053A (et) 1999-08-16
HK1023125A1 (en) 2000-09-01
CZ33499A3 (cs) 1999-06-16
JP2000506542A (ja) 2000-05-30
IL128255A0 (en) 1999-11-30
EP1283203A1 (fr) 2003-02-12
AP9901458A0 (en) 1999-03-31
US20010003752A1 (en) 2001-06-14
LV12274B (en) 1999-09-20
EA200000891A1 (ru) 2001-02-26
JP2005015497A (ja) 2005-01-20
KR100383148B1 (ko) 2003-05-09
NO990541L (no) 1999-02-05
IS4961A (is) 1999-01-29
DK0920422T3 (da) 2003-03-17
AP1055A (en) 2002-04-04
OA11298A (en) 2003-10-22
DE69717281D1 (de) 2003-01-02
CA2264104A1 (fr) 1998-02-19
IS1989B (is) 2005-02-15
KR20000029994A (ko) 2000-05-25
LV12274A (lv) 1999-05-20
IL161224A0 (en) 2004-09-27
RS49671B (sr) 2007-11-15
US6441014B2 (en) 2002-08-27
BG103155A (en) 1999-11-30
BR9711151A (pt) 1999-08-17
ATE228117T1 (de) 2002-12-15
RO120771B1 (ro) 2006-07-28
SI9720059B (sl) 2011-11-30
CN1205193C (zh) 2005-06-08
HUP0400923A3 (en) 2007-11-28
EA199900200A1 (ru) 1999-06-24
CZ297679B6 (cs) 2007-03-07
NO990541D0 (no) 1999-02-05
JP3631763B2 (ja) 2005-03-23
LT99024A (en) 1999-07-26
DE69717281T2 (de) 2003-09-04
PL191313B1 (pl) 2006-04-28
TR199900298T2 (xx) 1999-05-21
EP0920422A1 (fr) 1999-06-09
UA52684C2 (uk) 2003-01-15
SK13699A3 (en) 1999-07-12
ES2188971T3 (es) 2003-07-01
BG64259B1 (bg) 2004-07-30
GEP20022636B (en) 2002-02-25
PT920422E (pt) 2003-03-31
PL331607A1 (en) 1999-08-02
EA003754B1 (ru) 2003-08-28
AU4093697A (en) 1998-03-06
US7135489B2 (en) 2006-11-14
NO312461B1 (no) 2002-05-13
IL128255A (en) 2004-06-20
YU7499A (sh) 2000-03-21
CN1233243A (zh) 1999-10-27
TW527350B (en) 2003-04-11
SK283558B6 (sk) 2003-09-11
ZA977314B (en) 1998-08-14

Similar Documents

Publication Publication Date Title
LT4551B (lt) 4-[5-metil-3-fenilizoksazol-4-il]benzensulfonamido kristalinė forma
EP0946507B1 (fr) Composes de pyrrolyle substitues destines au traitement de l'inflammation
EP1379513B1 (fr) Promedicaments de composes inhibiteurs de cyclooxygenase-2
JP4049307B2 (ja) Ｃｏｘ−２阻害剤のプロドラッグとしての置換ベンゼンスルホンアミド誘導体
JP3267300B2 (ja) 炎症の治療のための置換イソオキサゾール
US20070072921A1 (en) Crystalline form of 4-[5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide
MXPA99001526A (en) Crytalline form of 4-[5-methyl-3-phenylisoxazol-4-yl]benzenesulfonamide
EP1369415A1 (fr) Dérivés de pyrrole utilisés dans le traitement des inflammations

Legal Events

Date Code Title Description
PD9A Change of patent owner

Owner name: G.D. SEARLE & CO., US

Effective date: 20041001

SPCF Filing an spc

Free format text: PRODUCT NAME: VALDECOXIBUM ( 4-(5-METIL-3-FENIL-4-IZOKSAZOLIL)BENZENSULFONAMIDAS); REGISTRATION NO/DATE: 03/8255/7, 2003 09 09; 03/8256/7, 2003 09 09; 03/8257/7 20030909

Spc suppl protection certif: PA2004006

Filing date: 20041001

Expiry date: 20170812

ND9D Filing a supplementary protection certificate

Free format text: PRODUCT NAME: VALDECOXIBUM - 4-[5-METIL-3-FENIL-4-IZOKSAZOLIL]BENZENSULFONAMIDAS

Spc suppl protection certif: PA2004006

Filing date: 20041001

SPCG Grant of an spc

Free format text: PRODUCT NAME: VALDECOXIBUM ( 4-(5-METIL-3-FENIL-4-IZOKSAZOLIL)BENZENSULFONAMIDAS); REGISTRATION NO/DATE: 03/8255/7, 2003 09 09; 03/8256/7, 2003 09 09; 03/8257/7 20030909

Spc suppl protection certif: PA2004006,C4551

Filing date: 20041001

Expiry date: 20170812

Extension date: 20180908

MM9A Lapsed patents

Effective date: 20090812

SPCW Withdrawal of an spc

Free format text: PRODUCT NAME: VALDECOXIBUM ( 4-(5-METIL-3-FENIL-4-IZOKSAZOLIL)BENZENSULFONAMIDAS); REGISTRATION NO/DATE: 03/8255/7, 2003 09 09; 03/8256/7, 2003 09 09; 03/8257/7 20030909

Spc suppl protection certif: PA2004006,C4551

Filing date: 20041001

Expiry date: 20170812

Extension date: 20180908

Effective date: 20090812